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Abstract
Objective-To compare neutron treatment and
megavoltage (photon) radiotherapy in locally
advanced squamous cell carcinoma of the head and
neck.
Design-Randomised trial of patients stratified by
site of primary tumour and presence or absence of
lymph node metastases. Follow up of patients after
treatment.
Setting-Department of clinical oncology, Western
General Hospital, Edinburgh.
Patients- 165 Patients with untreated, histologic-
ally proved squamous cell carcinoma of the oral
cavity, oropharynx, larynx, or hypopharynx. All
patients completed treatment, and no patient was
lost to follow up.
Intervention-Treatment with either neutrons or
photons.
Main outcome measures-Disease state and
morbidity (scored with the system of the European
Organisation for Research on Treatment of Cancer)
at each visit during follow up.
Results-Of the 165 patients, 85 were randomised
to receive neutron treatment and 80 to receive
photon treatment. Minimum follow up was five
years. Local control of cancer remained similar in
the two groups, being achieved in 37 (44%) patients
after neutron treatment and 36 (45%) after photon
treatment. Five year and actuarial 10 year survival
rates were 24% (20/85) and 14% respectively in the
group treated with neutrons and 34% (27/80) and 30%
respectively in the group treated with photons. Five
year survival rates without local disease were 19%
(16/85) and 30% (24/80) respectively. Necrosis was
more common after neutron treatment than after
photon treatment. Seven patients in the neutron
group who developed necrosis died whereas no
deaths were associated with photon treatment.
Conclusion-Rates of long term local control were
similar in the two groups. Necrosis related to
radiation was more common in patients treated with
neutrons, and the mortality related to treatment was
significantly higher in these patients.
Introduction
This paper reports the results of a long term follow
up of patients admitted to a randomised trial at
the Medical Research Council's cyclotron unit in
Edinburgh from 1977 to 1984. In 1987 we reported
details of the selection and characteristics of patients,
randomisation, treatment techniques, doses, and
fractionation schedules.' The trial was undertaken
after a report of improved control of advanced head
and neck cancer after neutron treatment at the Medical
Research Council's cyclotron unit at Hammersmith
Hospital, London.' It was designed to include some
patients with less advanced disease than that of patients
recruited to the London trial so that long term
local control of cancer and morbidity could be more
accurately assessed. The fractionation schedule was
identical for both groups. It was decided that the
neutron doses used in Edinburgh should be, on
average, 5% lower than those used at Hammersmith
Hospital because of the high morbidity recorded
there.3
The estimation of the size of the trial was based on a
predicted enhancement of local control of cancer from
40% (found with photon treatment in Edinburgh) to
70% (found with neutron treatment at Hammersmith
Hospital). It was calculated that 164 patients were
required ifthis difference was to be significant (a= 0 02,
power 90%) in a two tailed test of significance.
Patients and methods
Patients who had untreated, histologically proved
squamous carcinoma in the oral cavity, oropharynx,
larynx, or hypopharynx were eligible. They had to be
under 80 years old and judged fit for a radical course of
radiotherapy. All patients were assessed initially by a
referring otolaryngologist or oral surgeon and then by
at least two of the radiation oncologists responsible for
this study before they were judged suitable for inclusion
in the trial. Written informed consent was obtained
from all patients. Overall, 165 eligible patients were
analysed; 85 were treated with neutrons and 80 with
photons. The distribution of patients by age, site, and
T and N classification of tumours and nodes was
similar in the two groups.
All treatments were given in 20 daily fractions over
four weeks. The total absorbed dose (n+y) of neutrons
ranged from 15 6 Gy to 16 7 Gy and that of photons
from 54 Gy to 56 Gy, depending on the site and the size
of the field. All patients completed treatment as
planned.
Follow up assessment was carried out at intervals
defined by the protocol by the same team of radiation
oncologists. Disease state and morbidity (scored with
the system of the European Organisation for Research
on Treatment of Cancer4) were assessed at each visit.
The minimum follow up was five years and the
maximum 11 years. No patient was lost to follow
up.
Results
Long term rates of local control were similar in the
two groups (table I). Overall, 37 of the 85 patients
(44%) treated with neutrons and 36 of the 80 patients
treated with photons had sustained local control. The
95% confidence interval for the difference of 1% in
favour for photon treatment was large (- 14% to 17%).
There was no significant difference in control rates by
site.
Two apparent late recurrences oftumours within the
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TABLE I-Rates of local control and occurrence ofnecrosis by site oftumour in patients treated with neutrons
or photons (percentages ofpatients in parentheses)
Neutron treatment Photon treatment
No of Local No of Local
Site patients control Necrosis patients control Necrosis
Oral cavitv 32 12 (38) 8 (25) 34 15 (44) 3 (9)
Oropharynx 21 9 (43) 4 (19) 14 6 (43) 2 (14)
Larynx 21 11 (52) 4 (19) 22 12 (55) 3 (14)
Hypopharvnx 11 5 (45) 2 (18) 10 3 (30) 1 (10)
Total 85 37 (44) 18 (21) 80 36 (45) 9 (11)
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FIG 1 -Actuarial cause specific survival rates in patients treated with
photons or neutrons
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FIG 2-Cumulating incidence of necrosis in mucosa or laryngeal
cartilage in patients treated with photons or neutrons
treated area were seen in the group treated with
neutrons, one seven years and one nine years after
treatment. The histological features of one of these
tumours was completely different from those of
the original tumour. Immunohistochemical studies
suggested a mesenchymal origin, and a presumptive
diagnosis of soft tissue sarcoma was made. No late
recurrences were seen in the patients treated with
photons.
The five year survival rate was 24% after treatment
with neutrons (20/85) and 34% after treatment with
photons (27/80). The actuarial 10 year survival rates
were 14% and 30% respectively (p=007, log rank
test). The survival rate without local disease at five
years was 19% (16/85) (95% confidence interval 11% to
27%) for patients treated with neutrons and 30%
(24/80) (20% to 40%) for those treated with photons.
Figure 1 shows the actuarial cause specific survival
rates up to 10 years (p=0 35, log rank test).
In the group treated with neutrons 18 patients
developed late radiation necrosis (grade 4, European
Organisation for Research on Treatment of Cancer
system) in the mucosa or laryngeal cartilage compared
with nine patients in the group treated with photons
(table I). Figure 2 shows the cumulative incidence of
necrosis, calculated by the inverted life table method.
At two years the incidence was 25% in the group
treated with neutrons and 13% in the group treated
with photons, and at five years the figures were 29%
and 13% respectively (p=0 07, log rank test). Although
the rate of necrosis in the two groups was not
significantly different, the subsequent mortality was
significantly higher in the patients treated with
neutrons. Seven patients treated with neutrons who
developed late radiation necrosis were judged to have
died as a direct consequence. One of these had necrosis
of the mandible. None of the patients treated with
photons died as a result of late radiation necrosis.
Table II shows the outcome in patients who developed
necrosis by treatment.
TABLE iI-Outcome in patients who developed necrosis by treatment
Neutron Photon
Outcome treatment treatment Total
Alive:
Healed or conservative treatment 32 5
After surgery 2 2 4
Dead:
Intercurrent disease 2 2 4
Recurrent cancer 4 3 7
Radiation necrosis 7 7
Total 18 9 27
Discussion
There is no evidence in this study of a therapeutic
advantage for treatment with neutrons. Tumour
control rates and cause specific survival rates were
similar in the two groups. Control of tumours after
photon treatment (45%) agreed with the expected
results used in the design of the trial (40%), but control
after neutron treatment (44%) did not reach that
predicted by the study at Hammersmith Hospital. The
late recurrence of a tumour in one patient and apparent
sarcoma in another in the irradiated area in the group
treated with neutrons are unusual. The diagnosis of
soft tissue sarcoma is a cause for concern as it may be
related to the treatment using high linear energy
transfer neutrons.
Although the overall rate of necrosis was not signifi-
cantly worse in the patients treated with neutrons, a
significant difference in mortality related to treatment
was seen. Despite giving a lower dose of neutrons than
that at Hammersmith Hospital we also found a high
mortality related to treatment, although it was less than
that reported by the Medical Research Council's
working group in its assessment of the Hammersmith
Hospital study.4
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